KYTX
KYVERNA THERAP (KYTX)
NASDAQ
$7.91+$0.010 (+0.13%)
Price as of Jun 03, 2026 7:42 PM EDT
  • $518.0M
    Market Cap
  • 183.15%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
Research and Development Expense
-133.7M
+18.89%
-112.5M
N/A
Depreciation and Amortization Expense
1.8M
-15.66%
2.1M
N/A
Total Operating Expenses
169.8M
+19.09%
142.6M
N/A
Operating Profit
-169.8M
+19.09%
-142.6M
N/A
Interest Income
9.1M
-40.79%
15.4M
N/A
Interest Expense
-400,000
N/A
N/A
N/A
Interest Income and Expense and Net
8.7M
-43.39%
15.4M
N/A
Total Nonoperating Income and Expense
8.5M
-43.68%
15.1M
N/A
Income before Taxes
-169.8M
+19.09%
-142.6M
N/A
Income Taxes
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
Net Income
-161.3M
+26.54%
-127.5M
N/A
Net Income from Continuing Operations Applicable to Common
-161.3M
+26.54%
-127.5M
N/A
Basic EPS and Net Income
-3.64
+9.31%
-3.33
N/A
Diluted EPS and Net Income
-3.64
+9.31%
-3.33
N/A
Basic Weighted Average Shares
44.3M
+15.46%
38.3M
N/A
Diluted Weighted Average Shares
44.3M
+15.46%
38.3M
N/A
Balance Sheet
Cash and Cash Equivalents
124.1M
+28.43%
96.6M
N/A
Short-Term Investments
155.2M
-18.06%
189.4M
N/A
Cash and Cash Equivalents and Short-Term Investments
279.3M
-2.35%
286.0M
N/A
Total Current Assets
283.0M
-2.63%
290.6M
N/A
Accumulated Depreciation
3.8M
+2.12%
3.7M
N/A
Property and Plant and Equipment and Net
1.5M
-53.81%
3.3M
N/A
Total Long-Term Assets
4.9M
+72.88%
2.8M
N/A
Total Assets
293.8M
-3.55%
304.6M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
Total Short-Term Debt
24.7M
N/A
N/A
N/A
Total Current Liabilities
36.5M
+8.09%
33.8M
N/A
Total Long-Term Debt
24.7M
N/A
N/A
N/A
Total Long-Term Liabilities
320,000
-92.31%
4.2M
N/A
Total Liabilities
61.5M
+61.73%
38.1M
N/A
Retained Earnings
-424.8M
+61.21%
-263.5M
N/A
Total Stockholders Equity
232.3M
-12.87%
266.6M
N/A
Total Shares Outstanding
60.4M
+39.74%
43.2M
N/A
Cash Flow
Cash from Operating Activities
-153.7M
+34.54%
-114.3M
N/A
Capital Expenditures
5,000
-99.77%
2.2M
N/A
Cash from Investing Activities
40.0M
+124.87%
-160.9M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
Cash from Financing Activities
141.2M
-58.12%
337.1M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
Return on Assets
-53.91%
N/A
N/A
N/A
Return on Equity
-64.67%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
Current Ratio
7.75
N/A
N/A
N/A
Cash Ratio
3.40
N/A
N/A
N/A
Debt-to-Equity Ratio
0.21
N/A
N/A
N/A
Debt-to-Assets Ratio
0.17
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow